Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am at a loss for words that a great product can be mismanaged. Operating expenses are still way too high. Not sure what to think. If they can't manage the marketing mix, properly, and spend way too much. It must be very close to a bottom when I post this.
Congrats Dew! I bought in on the dip today and going to hold for a while.
Now that BW is gone, what are you going to do?
ALLK has $500 million in cash. $20 pt?
Buying these dips. Finally a chance to get in much lower than it was.
Hi, Dew long time since I have posted, but thank you for your very helpful posts. Sincerely, FR
EOLS on the move. Not seeing news.
Unless you are Tom Hanks...the chosen few
Some suggest it's a "botox clone"
$100 seems ridiculous, but if they produce, and I think they will with such a differentiated product, the market cap won't be overdone like a lot of tech stocks. We shall see.
RVNC..the market cap is so cheap that it is surreal. I know it's cliche to say that it's a gift at today's price, even better when it was $10, but I think it has $40 this year. The stock seems like it is flying under the radar for now. Thanks to Roy for pointing out the stock and all of the dd he brought. I truly believe it will go $100 easily with their superior product and deals. The relatively low outstanding share count is a real plus.
The "coronavirus" stocks are laughable as GILD has more in its dusty lab closet for coronavirus treatments than all of the other scam stocks put together.
I'm surprised they haven't announced the submission to the FDA. It leaves uncertainty. Guess we will see.
Looking good and just at the beginning of the vast array of catalysts for 2020.
I know that the mj industry is taking a hit and it's affecting most of the stocks. The up listing should help a lot.
This company makes a nice profit, has sequential q/q growth, y/y growth and yet it is taking a hit? Compared to most companies in the MJ space, MEDIF is way undervalued. Why is it getting hit so hard? Is there convertible financing or an ATM? Just trying to wrap my head around this stock price. My avg is 3.15 and can't believe the price is below that.
Considering the company's sequential growth, yoy growth, contracts, and superior fundamentals to a lot of companies, why isn't the stock price at $10? Being on the OTC is the only reason that makes sense.
With the protest over, no reason to sell, unless a peanut trader is playing.
Nibbled long in a position today. Good luck all!
AMRN is shaping up just like RLYP. When you least expect it, the buyout will occur. Enjoy!
The key takeaway here is that investors shouldn't sweat this capital raise. Amarin has proven to be a winning play for biopharma investors and this capital raise only creates more avenues for value creation in the years to come. Lastly, there's no reason to believe that a capital raise has any bearing on possible buyout talks -- other than the fact that Amarin would now be negotiating from a position of strength.
https://www.nasdaq.com/article/amarin-is-a-buyout-really-off-the-table-cm1179844
Oh yeah that's the info that he claims to have but can't share lmao
I wonder how much Sigo charged for said hit piece and who paid for it?
Nose runner doesn't like to share his so-called "sell-through data" to support his "facts". So shocking and makes the guy fired by BW lose credibility.
The company had a prearranged offering which put a lid on the price. It was a small offering, plus they had a convertible deal with a discount that ends today. Keep in mind this is a tiny company with capital needs, and no guarantee the FDA would approve their product. The stock price should start to melt upward with the selling pressure easing soon. Also, the company is going on the Russell Micro Cap Index starting July 1. The stock should get some demand. Anyway, Esocheck is going to be a good product for PAVM.
FDA Approval. A new beginning for this company in a multi-billion addressable market. Esocheck clearly superior to the competitor's simple sponge product lol. I wouldn't be surprised if we hear of a partnership soon!
NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has received 510(k) marketing clearance for its EsoCheck Cell Collection Device™ (“EsoCheck”) from the U.S. Food and Drug Administration (FDA).
“I have spent my career seeking to improve the care of patients with gastroesophageal reflux disease and Barrett’s Esophagus and to prevent deaths from esophageal cancer. I have actively participated in the development of key advances in this field and am particularly excited that EsoCheck is now available as an FDA-cleared tool in our armamentarium. EsoCheck’s unique ability to sample cells from a targeted area of the esophagus has the potential to save lives through the early detection of esophageal abnormalities,” said Nicholas J. Shaheen MD, MPH, Professor of Medicine and Epidemiology and Chief of the Division of Gastroenterology and Hepatology at the University of North Carolina School of Medicine, Director of American College of Gastroenterology (ACG) Institute for Clinical Research and Education.
EsoCheck is a non-invasive cell collection device that is designed to sample cells from a targeted region of the esophagus in a five-minute office-based procedure, without the need for endoscopy. The patient swallows a vitamin pill-sized capsule containing a small inflatable balloon attached to a thin catheter. As the catheter is withdrawn, it swabs the target area for a sample of cells and protects that sample from contamination as the device is removed. The sampled cells can then be subjected to any commercially available diagnostic test. FDA determined that EsoCheck is substantially equivalent to legally marketed predicate devices for its indications for use, namely “the collection and retrieval of surface cells of the esophagus in the general population of adults, 22 years of age or older”.
“I am excited to report this major milestone for PAVmed and Lucid,” said Lishan Aklog, MD, PAVmed’s Chairman and CEO and Lucid’s Executive Chairman. “We are proud to have received FDA clearance for EsoCheck just over one year from the day we founded Lucid and licensed this groundbreaking technology from Case Western Reserve University. We look forward to offering EsoCheck to physicians and patients this summer and believe EsoCheck presents many advantages over existing sponge-on-a-string esophageal cell collection devices. These devices have a capsule which must be digested in the stomach before it can be used to sample cells, while EsoCheck can begin sampling immediately upon insertion. More importantly, EsoCheck’s Collect+Protect™ technology allows it to perform a targeted sample of the lower esophagus, while spherical sponge-on-a-string devices sample cells from the entire esophagus, throat and mouth which dilutes and contaminates the lower esophageal cells.”
About PAVmed
PAVmed Inc. is a highly differentiated, multiproduct medical device company employing a unique business model designed to advance innovative products to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation. PAVmed’s diversified pipeline of products address unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its five lead technologies provide groundbreaking approaches to carpal tunnel syndrome (CarpX™), precancerous conditions of the esophagus (EsoGuard™/EsoCheck™), vascular access (PortIO™), pediatric ear infections (DisappEAR™) and medical infusions (NextFlo™). The company is also developing innovative products in other areas, such as catheters and tissue ablation, while seeking to further expand its pipeline through engagements with clinician innovators and leading academic medical centers. For more information, please visit www.pavmed.com, follow us on Twitter, connect with us on LinkedIn, and watch our videos on YouTube.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of PAVmed’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed’s common stock, Series W Warrants and Series Z Warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required advance PAVmed’s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed’s preclinical studies; whether and when PAVmed’s products are cleared by regulatory authorities; market acceptance of PAVmed’s products once cleared and commercialized; our ability to raise additional funding and other competitive developments. PAVmed has not yet received clearance from the FDA or other regulatory body to market any of its products. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond PAVmed’s control. For a further list and description of these and other important risks and uncertainties that may affect PAVmed’s future operations, see Part I, Item IA, “Risk Factors,” in PAVmed’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Reports on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
Contacts:
Investors
Mike Havrilla
Director of Investor Relations
(814) 241-4138
JMH@PAVmed.com
Media
Shaun O’Neil
Chief Commercial Officer
(518) 812-3087
SMO@PAVmed.com
https://finance.yahoo.com/news/pavmed-subsidiary-lucid-diagnostics-receives-144650232.html
My skills are good but not that good :)
Stock price just crossed the 50 MA. This is going to move nicely.
Looks like my post was near the beginning of the new uptrend. See you at $20 this year.
I've followed RVNC for over a year and wondered why it's being punished? Seems like the market for the product is well protected from new entrants as the requirements for the manufacturing seem to be stiff? Competition is always welcome by providers as they want additional options in their treatment armamentarium.
Any thoughts on why the stock has gone up the last three days? I was hoping to buy some way under $10? The next catalyst isn't until 2020?
If they get approval, seems like a good opportunity..at least it will eventually move like EOLS did (not comparing RVNC to EOLS). In my opinion, EOLS is uninvestable as the issue in Korea is not clear.
All thoughts are welcome and I do empathize with the beating the stock price has taken.
Origin House (ORHOF)
Origin House, a Canadian branding and distribution company, is set to be acquired by Cresco Labs (CRLBF), pending a review by U.S. antitrust authorities. The company is known for its strategic moves, Parry says. "Origin House was always a year ahead of everyone else," he says. "When others were grabbing licenses, they were extracting. When others were chasing extractions, they were buying labs and value added products and brands that people liked." The company has flipped assets for a profit and built others – beating the trends. "That they're now being acquired doesn't mean they cease to be – it means they're bigger and going to be much more important as Cresco Labs," Parry says.
https://money.usnews.com/investing/stock-market-news/slideshows/6-companies-that-support-the-marijuana-business?slide=5&src=usn_tw
Bought a bunch lower and holding. CRLBF has a sharp management team and the current low stock price of their company and ORHOF insults their intelligence and competence. Stock price will melt upward imo.
I'm going to load up if hits 5's tomorrow. The fundamentals and prospects of the company are better than ever. Just a big shot dumping on the ask. That means the stock price will go up fast once he/she is done imo.
It's frustrating because nothing has changed for ORHOF. Canada just approved the merger and the Feds will approve it. It's a big holder unloading. Once the seller is done, it will rise fast imo. It's just not clear how much more this person has left to sell.
Tiresome to watch someone load the ask and sell all day. One person is holding the stock hostage while he/she is liquidating. GTH!!!!
AGN can leverage its huge sales force to seed doubt. The reps will just throw the equivalent of FUD to the providers. RVNC will need to partner to have the share of voice necessary to counter that crap. RVNC doesn't have a choice unfortunately.
Overreaction and bounce imminent imo..
NBEV may become the next HLF. Carl Icahn...do your thing and buy NBEV!!!!!
weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee